Sara Hawley

Director, Scientific Communications & Exchange
BioMarin Pharmaceutical, Inc.

Presentation(s):

• PB0656 - Comparability of bleeding outcomes by prophylactic FVIII replacement intensity: A post-hoc analysis of a non-interventional study of men with severe hemophilia A

  Monday, July 11, 2022
  6:30 PM – 7:30 PM